CINCINNATI--(BUSINESS WIRE)--May 15, 2023--
Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of 10 directors at the Company’s 2023 annual stockholders’ meeting. New to the Board is Eileen McCarthy, Senior Vice President of UiPath, Inc. (NYSE: PATH).
Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company’s independent accountants for 2023. Stockholders also approved Chemed’s executive compensation and recommended the say-on-pay vote remain an annual vote. In addition, stockholders voted against the stockholder proposal on ratification of termination pay.
Dividend Declared
Following the stockholders’ meeting, Chemed’s Board of Directors declared a quarterly cash dividend of 38 cents per share on the Company’s capital stock, payable on June 14, 2023, to stockholders of record as of May 25, 2023. This represents the 208th consecutive quarterly dividend paid to stockholders in Chemed’s 52 years as a public company.
Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care, and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.
Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005531/en/
David P. Williams
(513) 762-6901
Source: Chemed Corporation
